- Colfax leadership is pleased with the continuing integration of DJO, noting “good engagement and associate feedback”
- Joint replacement growth driven by product innovation and relationships with key opinion leaders, including positive surgeon response to the EMPOWR knee
- Colfax’s operations improvement plan for DJO includes continuous improvement of procurement and supply chain, with a focus on the reimbursement process and product innovation
- Leadership noted that the DJO purchase gives them new directions to pursue acquisitions that can improve both the scale and reach of Colfax
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement | $81.8 | $73.4 | $8.4 | 11.5% |
| Knees | $21.2 | $19.2 | $2.0 | 10.5% |
| Hips | $18.0 | $16.6 | $1.4 | 8.4% |
| Extremities | $42.6 | $37.6 | $5.0 | 13.4% |
| Other (Recovery Sciences) | $22.4 | $22.5 | $0.0 | -0.1% |
| Total | $104.3 | $95.8 | $8.4 | 8.8% |
Sources: Colfax Corp.; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Colfax leadership is pleased with the continuing integration of DJO, noting “good engagement and associate feedback”
Joint replacement growth driven by product innovation and relationships with key opinion leaders, including positive surgeon response to the EMPOWR knee
Colfax’s operations improvement plan for DJO includes...
- Colfax leadership is pleased with the continuing integration of DJO, noting “good engagement and associate feedback”
- Joint replacement growth driven by product innovation and relationships with key opinion leaders, including positive surgeon response to the EMPOWR knee
- Colfax’s operations improvement plan for DJO includes continuous improvement of procurement and supply chain, with a focus on the reimbursement process and product innovation
- Leadership noted that the DJO purchase gives them new directions to pursue acquisitions that can improve both the scale and reach of Colfax
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | $ Chg | % Chg | |
| Joint Replacement | $81.8 | $73.4 | $8.4 | 11.5% |
| Knees | $21.2 | $19.2 | $2.0 | 10.5% |
| Hips | $18.0 | $16.6 | $1.4 | 8.4% |
| Extremities | $42.6 | $37.6 | $5.0 | 13.4% |
| Other (Recovery Sciences) | $22.4 | $22.5 | $0.0 | -0.1% |
| Total | $104.3 | $95.8 | $8.4 | 8.8% |
Sources: Colfax Corp.; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





